| Schedule of segment reporting information |
| Schedule of segment reporting information | |
| | | |
| | |
| | |
For the Year Ended | | |
For the Year Ended | |
| | |
June 30, 2025 | | |
June 30, 2024 | |
| | |
| | |
| |
| Clinical studies | |
$ | 3,660,000 | | |
$ | 11,081,000 | |
| Clinical teams | |
| 4,479,000 | | |
| 8,873,000 | |
| Chemistry, manufacturing and controls | |
| 834,000 | | |
| 2,066,000 | |
| Other research and development expenses | |
| 294,000 | | |
| 1,081,000 | |
| Selling, general and administrative expenses | |
| 8,570,000 | | |
| 8,850,000 | |
Amortization of intangible assets | |
| 229,000 | | |
| 229,000 | |
Other income, net | |
| (524,000 | ) | |
| (59,000 | ) |
Net loss | |
$ | (17,542,000 | ) | |
$ | (32,121,000 | ) |
|